Optimizing the Risk-Adjusted CUSUM for Monitoring Hospital Non-cardiac Perioperative Outcomes

优化风险调整 CUSUM 以监测医院非心脏围手术期结果

基本信息

  • 批准号:
    10315667
  • 负责人:
  • 金额:
    $ 8.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

National surgical quality improvement (QI) programs, such as the Veterans Affairs (VA) Surgical Quality Improvement Program (VASQIP) and the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), collect, analyze, and provide hospitals with institution-level, risk-adjusted data on perioperative morbidity and mortality in an episodic (e.g., quarterly) fashion. Hospitals in turn use these data to inform their local QI efforts. While this episodic approach to feedback is a convention in nearly all national surgical QI programs, it is associated with two important limitations: 1) a time lag between when hospital performance is declining and when notification is provided at the end of the quarterly data ascertainment period; 2) a limited ability to detect potentially meaningful clusters of adverse events that may go unrecognized with episodic evaluation strategies. One potential alternative analytic strategy that could supplement and enhance current approaches to surgical QI is the cumulative sum (CUSUM). The CUSUM is a statistical process control method that has been utilized in the industrial setting to provide real-time monitoring of the quality of production processes. In health care, the CUSUM has been used to ascertain when outcome variation is approaching an unacceptable level and is well-suited for detecting relatively small, yet persistent, changes in a given outcome over time. It is currently used by the United Network for Organ Sharing Membership and Profession Standard Committee, a regulatory body for transplant surgery in the United States, for monitoring hospital-level post-transplant patient and graft long-term survival in real-time. In addition, our group’s ongoing work has shown the CUSUM consistently provides early, meaningful, performance-based institutional feedback regarding perioperative outcomes. The overall goal of this proposal is to build upon our prior work by exploring how to optimize the CUSUM for use within national surgical QI programs to enable early and accurate detection of hospitals with poor performance. Using national VASQIP data, our goals are to: 1) evaluate whether multiple CUSUM signals in a given quarter decreases false positive hospital detection; 2) explore whether a continuously running CUSUM (over multiple quarters) decreases false positive hospital detection; 3) describe hospital factors associated with false positive and false negative CUSUM signaling. This work will help to inform a future prospective evaluation of the CUSUM and eventual implementation withing VASQIP. Leveraging VASQIP’s existing infrastructure to provide institutions with more real-time, actionable data could ultimately result in the detection of previously unappreciated suboptimal care processes and save patients from preventable morbidity and/or mortality.
国家手术质量改进(QI)计划,如退伍军人事务部(VA)手术质量 改进计划(VASQIP)和美国外科医师学会国家外科质量 改善计划(ACS NSQIP),收集、分析并向医院提供机构级的、风险调整后的 关于间歇性的围手术期发病和死亡的数据(例如,季度)时尚。医院反过来使用 这些数据,以告知他们的本地QI工作。虽然这种情景式的反馈方式几乎是所有 国家外科QI计划,它与两个重要的限制有关:1)当 医院绩效正在下降,当在季度数据结束时提供通知时, 确定期; 2)检测可能发生的潜在有意义的不良事件集群的能力有限 不被情景评价策略所认可。一种潜在的替代分析策略, 补充和增强当前外科QI的方法是累积和(Cumulative sum,CQUM)。该博物馆是 一种统计过程控制方法,已在工业环境中使用,以提供实时 监控生产过程的质量。在卫生保健领域, 当结果变化接近不可接受的水平并且非常适合于检测相对小的时, 然而,随着时间的推移,在给定的结果中持续变化。它目前由联合器官移植网络使用, 分享会员资格和专业标准委员会,一个在移植手术的监管机构, 美国,用于实时监测医院级移植后患者和移植物长期存活率。在 此外,我们小组正在进行的工作表明,该组织一贯提供早期的,有意义的, 关于围手术期结局的基于绩效的机构反馈。本提案的总体目标是 是在我们先前工作的基础上,探索如何优化在国家外科QI中使用的CAPSUUM 这些计划能够及早和准确地发现业绩不佳的医院。使用国家VASQIP 数据,我们的目标是:1)评估给定季度的多个CQUM信号是否减少错误 积极的医院检测; 2)探索是否连续运行的CIMUM(多个季度) 减少假阳性医院检测; 3)描述与假阳性和假阳性相关的医院因素 消极的信号。这项工作将有助于为今后对该研究所进行的前瞻性评价提供信息, 最终在VASQIP中实现。利用VASQIP现有的基础设施, 有了更多的实时、可操作的数据,最终可能会发现以前不被重视的问题, 不理想的护理过程,使患者免于可预防的发病和/或死亡。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Vivi Chen其他文献

Vivi Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Vivi Chen', 18)}}的其他基金

Optimizing the Risk-Adjusted CUSUM for Monitoring Hospital Non-cardiac Perioperative Outcomes
优化风险调整 CUSUM 以监测医院非心脏围手术期结果
  • 批准号:
    10448264
  • 财政年份:
    2021
  • 资助金额:
    $ 8.24万
  • 项目类别:

相似国自然基金

The Heterogenous Impact of Monetary Policy on Firms' Risk and Fundamentals
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    万元
  • 项目类别:
    外国学者研究基金项目
基于时间序列间分位相依性(quantile dependence)的风险值(Value-at-Risk)预测模型研究
  • 批准号:
    71903144
  • 批准年份:
    2019
  • 资助金额:
    17.0 万元
  • 项目类别:
    青年科学基金项目
RISK通路在胃泌素介导的心脏缺血再灌注损伤保护中的作用研究
  • 批准号:
    81800239
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
异氟烷基于TLR4/RISK/NF-κB调控糖尿病缺血性脑卒中后NLRP3炎症小体形成的机制研究
  • 批准号:
    81771232
  • 批准年份:
    2017
  • 资助金额:
    54.0 万元
  • 项目类别:
    面上项目
Notch1与RISK/SAFE/HIF-1α信号通路整合在I-postC保护中的作用及其机制
  • 批准号:
    81260024
  • 批准年份:
    2012
  • 资助金额:
    50.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
  • 批准号:
    10292270
  • 财政年份:
    2021
  • 资助金额:
    $ 8.24万
  • 项目类别:
Optimizing the Risk-Adjusted CUSUM for Monitoring Hospital Non-cardiac Perioperative Outcomes
优化风险调整 CUSUM 以监测医院非心脏围手术期结果
  • 批准号:
    10448264
  • 财政年份:
    2021
  • 资助金额:
    $ 8.24万
  • 项目类别:
Machine learning for risk-adjusted breast MRI screening
用于风险调整乳房 MRI 筛查的机器学习
  • 批准号:
    10521264
  • 财政年份:
    2020
  • 资助金额:
    $ 8.24万
  • 项目类别:
Machine learning for risk-adjusted breast MRI screening
用于风险调整乳房 MRI 筛查的机器学习
  • 批准号:
    10316235
  • 财政年份:
    2020
  • 资助金额:
    $ 8.24万
  • 项目类别:
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
  • 批准号:
    9886161
  • 财政年份:
    2018
  • 资助金额:
    $ 8.24万
  • 项目类别:
HNA: Development and evaluation of methods to assess the quality of audit data used to calculate risk-adjusted performance indicators
海航:开发和评估用于计算风险调整绩效指标的审计数据质量的方法
  • 批准号:
    MR/R013489/1
  • 财政年份:
    2018
  • 资助金额:
    $ 8.24万
  • 项目类别:
    Research Grant
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
  • 批准号:
    10372989
  • 财政年份:
    2018
  • 资助金额:
    $ 8.24万
  • 项目类别:
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
对低危 HPV 相关口咽鳞状细胞癌患者进行择期容量调整降阶梯放射治疗 (EVADER) 的 II 期单臂试验
  • 批准号:
    379719
  • 财政年份:
    2018
  • 资助金额:
    $ 8.24万
  • 项目类别:
    Operating Grants
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
对低危 HPV 相关口咽鳞状细胞癌患者进行择期容量调整降阶梯放射治疗 (EVADER) 的 II 期单臂试验
  • 批准号:
    379021
  • 财政年份:
    2017
  • 资助金额:
    $ 8.24万
  • 项目类别:
    Operating Grants
Measurement that Matters: Retooling Risk Adjusted Outcome Measures to Support Practical Data Collection through Electronic Health Records
重要的衡量标准:重组风险调整结果衡量标准以支持通过电子健康记录进行实际数据收集
  • 批准号:
    9039542
  • 财政年份:
    2015
  • 资助金额:
    $ 8.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了